A novelty song that defines Halloween, ‘Monster Mash’ was recorded by Bobby ‘Boris’ Pickett in less than an hour. It got banned by the BBC, but refuses to die. We say “we’ve created a ...

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing up to pursue yet another indication for its star GLP-1 medicine semaglutide.

In its second full quarter on the market, the metabolic dysfunction-associated steatohepatitis (MASH) therapy racked up sales of $62 million, which “blew away,” Wall Street’s expectations ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Topline results were announced from part 1 of a phase 3 clinical trial evaluating subcutaneous semaglutide in patients with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis.

Summary results disclosed in a press release show that semaglutide met both of its main goals in the first part of a late-stage, placebo controlled study of people with metabolic ...

The "Monster Mash" was more than just a graveyard smash — it was also banned in the U.K. for many years! Learn about the Halloween track's unexpected origins Michael Ochs Archives/Getty Every ...

The blockbuster Novo Nordisk obesity drug Wegovy has met the main goals of a pivotal test in metabolic dysfunction steatohepatitis, or MASH, results the drugmaker says support expanding the ...

Astrazeneca plc has developed a potent oral fibroblast activation protein (FAP) inhibitor, AZD-2389, that avoids the cleavage of FGF21 and α2-AP. AZD-2389 was tested in cynomolgus monkeys with ...